Last reviewed · How we verify
Irinotecan liposome II combination therapy regimen
Irinotecan liposome II combination therapy regimen is a Small molecule drug developed by Peking Union Medical College Hospital. It is currently in Phase 2 development.
At a glance
| Generic name | Irinotecan liposome II combination therapy regimen |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer (PHASE2)
- A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (PHASE2)
- Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy (PHASE1, PHASE2)
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (PHASE1, PHASE2)
- Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma (PHASE2)
- A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen (PHASE2)
- Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irinotecan liposome II combination therapy regimen CI brief — competitive landscape report
- Irinotecan liposome II combination therapy regimen updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI
Frequently asked questions about Irinotecan liposome II combination therapy regimen
What is Irinotecan liposome II combination therapy regimen?
Irinotecan liposome II combination therapy regimen is a Small molecule drug developed by Peking Union Medical College Hospital.
Who makes Irinotecan liposome II combination therapy regimen?
Irinotecan liposome II combination therapy regimen is developed by Peking Union Medical College Hospital (see full Peking Union Medical College Hospital pipeline at /company/peking-union-medical-college-hospital).
What development phase is Irinotecan liposome II combination therapy regimen in?
Irinotecan liposome II combination therapy regimen is in Phase 2.